EE592 Long-Term Health and Economic Benefits of Switching to Tenofovir Alafenamide Versus Continuing on Entecavir in Chronic Hepatitis B Patients With Low-Level Viremia in Saudi Arabia
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.831
https://www.valueinhealthjournal.com/article/S1098-3015(22)03035-2/fulltext
Title :
EE592 Long-Term Health and Economic Benefits of Switching to Tenofovir Alafenamide Versus Continuing on Entecavir in Chronic Hepatitis B Patients With Low-Level Viremia in Saudi Arabia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03035-2&doi=10.1016/j.jval.2022.09.831
First page :
Section Title :
Open access? :
No
Section Order :
10371